All In Biotech

Drug Trial Radar · NCT04634552

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

510

Planned (sponsor's estimate)

Start

Feb 1, 2021

Primary completion

Jun 30, 2027

Study completion Mar 30, 2029

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Nov 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).

Conditions

  • Hematological Malignancies

Interventions

  • TalquetamabDrug

    Talquetamab will be administered SC until disease progression.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: Up to 2 years and 10 months

Locations

78 sites in 11 countries. Site status is shown where the registry gives one.

  • University of Alabama Birmingham

    Birmingham, Alabama · Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • City of Hope

    Duarte, California · Completed

  • Memorial Healthcare System

    Hollywood, Florida · Recruiting

  • Emory University Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • University of Chicago

    Chicago, Illinois · Completed

  • Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • University of Michigan Health System

    Ann Arbor, Michigan · Recruiting

  • Washington University School Of Medicine

    St Louis, Missouri · Recruiting

  • NYU Langone Health

    New York, New York · Active not recruiting

  • Mount Sinai Medical Center

    New York, New York · Recruiting

  • University of Rochester Medical Center

    Rochester, New York · Recruiting

  • Providence Portland Medical Center

    Portland, Oregon · Completed

  • Tennessee Oncology

    Nashville, Tennessee · Completed

  • UZ Antwerpen

    Edegem, Belgium · Completed

  • UZ Leuven

    Leuven, Belgium · Active not recruiting

  • CHU de Liège - Domaine Universitaire du Sart Tilman

    Liège, Belgium · Active not recruiting

  • UCL - Saint Luc

    Woluwe-Saint-Lambert, Belgium · Completed

  • Peking University Third Hospital

    Beijing, China · Completed

  • Sun Yat Sen University Cancer Center

    Guangzhou, China · Active not recruiting

  • The 1st Affiliated Hospital Of Medical College Zhejiang University 1

    Hangzhou, China · Active not recruiting

  • The 1St Affiliated Hospital of Medical College Zhejiang University

    Hangzhou, China · Active not recruiting

  • First Affiliated Hospital SooChow University

    Suzhou, China · Active not recruiting

  • Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Science

    Tianjin, China · Active not recruiting

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, China · Completed

  • The First Affiliated Hospital of Xian Jiaotong University

    Xi'an, China · Completed

  • CHU Henri Mondor

    Créteil, France · Active not recruiting

  • Hospices Civils de Lyon HCL

    Lyon, France · Active not recruiting

  • CHU de Montpellier Hopital Saint Eloi

    Montpellier, France · Active not recruiting

  • C.H.U. Hotel Dieu - France

    Nantes, France · Active not recruiting

  • CHU de Bordeaux - Hospital Haut-Leveque

    Pessac, France · Active not recruiting

  • Pôle IUC Oncopole CHU

    Toulouse, France · Active not recruiting

  • Charite Campus Benjamin Franklin

    Berlin, Germany · Active not recruiting

  • Universitaetsklinikum Heidelberg

    Heidelberg, Germany · Active not recruiting

  • Universitaetsklinikum Muenster

    Münster, Germany · Completed

  • Universitatsklinikum Wurzburg

    Würzburg, Germany · Active not recruiting

  • Rambam Medical Center

    Haifa, Israel · Active not recruiting

  • Carmel Medical Center

    Haifa, Israel · Active not recruiting

  • Hadassah Medical Center

    Jerusalem, Israel · Active not recruiting

  • Sheba Medical Center

    Ramat Gan, Israel · Active not recruiting

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.